RX Processing Corp.’s CEO, Peter Fiorillo, is taking an extraordinary step to champion the Dorgan-Snowe bill, legislation aimed at legalizing prescription drug importation into the United States. Fiorillo has launched a unique campaign, offering citizens a chance to win his first year’s salary, equivalent to 500,000 shares of company stock, currently valued at approximately $100,000.
Fiorillo’s initiative seeks to amplify the grassroots movement spearheaded by RX Processing Corp. and numerous other organizations dedicated to making prescription drugs more accessible and affordable for Americans. RX Processing Corp. connects Americans with licensed pharmacies and a trusted Canadian pharmacy group, facilitating access to medications from safe, cost-effective sources outside the U.S.
Many countries, including Canada, offer the same medications at significantly lower prices. According to Fiorillo, Canadian drug safety standards meet or exceed those of the U.S. Food and Drug Administration (FDA).
The escalating cost of prescription drugs in the U.S. is a growing concern, particularly among senior citizens on fixed incomes and those lacking comprehensive prescription drug coverage. An estimated 43 million Americans are uninsured, and millions more have inadequate coverage, forcing difficult choices between essential medications and other necessities.
Despite the demand for affordable medication, current FDA regulations discourage the importation of prescription drugs. The Dorgan-Snowe bill aims to rectify this by allowing the importation of drugs from Canada, where prices can be 30% to 80% lower. This legislation seeks to foster competition and choice within the healthcare industry. The bill’s creation was driven by increasing public pressure, with significant support from grassroots efforts within the senior community.